Show simple item record

dc.contributor.authorCulpepper, Larry
dc.contributor.authorVieta, Eduard
dc.contributor.authorKelly, Deanna L
dc.contributor.authorPatel, Mehul D
dc.contributor.authorSzatmári, Balázs
dc.contributor.authorHankinson, Arlene
dc.contributor.authorEarley, Willie R
dc.date.accessioned2022-05-24T12:35:03Z
dc.date.available2022-05-24T12:35:03Z
dc.date.issued2022-05-12
dc.identifier.urihttp://hdl.handle.net/10713/18989
dc.description.abstractBackground: Many medications used to treat schizophrenia and bipolar I disorder are linked to hyperprolactinemia. The effects of cariprazine, a dopamine D3/D2 receptor partial agonist, on prolactin levels in patients with schizophrenia or bipolar I disorder were evaluated. Methods: Effects on prolactin were evaluated using pooled data from randomized, double-blind, placebo-controlled studies in patients with schizophrenia (4 studies; 6-week duration; cariprazine 1.5-3 mg/d, 4.5-6 mg/d, and 9-12 mg/d), bipolar mania (3 studies; 3-week duration; cariprazine 3-6 and 9-12 mg/d), and bipolar depression (3 studies; 6- to 8-week duration; cariprazine 1.5 and 3 mg/d). Long-term effects were analyzed using open-label studies in patients with schizophrenia (2 studies; 48-week duration) and patients with bipolar mania (1 study; 16-week duration). Change in prolactin levels (ng/mL) from baseline to study endpoint was evaluated in subsets of sex and prior medication use. Results: In patients with schizophrenia (male, n = 1377; female, n = 558), median prolactin changes were -1.2 for males and -7.4 for females on placebo, and ranged from -4.2 to -3.6 for males and -12.4 to +0.2 for females in the cariprazine-treatment groups. In patients with bipolar mania (male, n = 570; female, n = 395), median prolactin changes were -0.2 for males and -1.1 for females on placebo and ranged from -2.1 to -3.0 for males and 0 to +1.8 for females in the cariprazine-treatment groups. Median decreases were also seen in the long-term studies of schizophrenia (range, -14.6 to -2.0) and bipolar mania (range, -0.8 to +1.9). In patients with bipolar depression (male, n = 485; female, n = 780), median prolactin changes were +0.3 for males and +0.7 for females on placebo and ranged from +0.4 to +0.5 for males and +3.0 to +3.1 for females in the cariprazine-treatment groups. Conclusion: Treatment with cariprazine for schizophrenia or bipolar I disorder was associated with minimal effects on prolactin levels.en_US
dc.description.urihttps://doi.org/10.2147/NDT.S348143en_US
dc.language.isoenen_US
dc.publisherDove Pressen_US
dc.relation.ispartofNeuropsychiatric Disease and Treatmenten_US
dc.rights© 2022 Culpepper et al.en_US
dc.subjectdepressionen_US
dc.subjectdopamineen_US
dc.subjectmaniaen_US
dc.subjectprolactinen_US
dc.subjectserotoninen_US
dc.titleMinimal Effects of Cariprazine on Prolactin Levels in Bipolar Disorder and Schizophrenia.en_US
dc.typeArticleen_US
dc.identifier.doi10.2147/NDT.S348143
dc.identifier.pmid35591886
dc.source.journaltitleNeuropsychiatric disease and treatment
dc.source.volume18
dc.source.beginpage995
dc.source.endpage1011
dc.source.countryNew Zealand


This item appears in the following Collection(s)

Show simple item record